Pfizer
NEWS
Researchers are continuing to develop next-generation therapeutics and oral vaccines that could overcome some vaccine hesitancy. Here are some of the top producers.
Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 27, 2021.
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.
Executives at pharmaceutical companies are known for receiving large salaries. When bonuses and stock options are factored into the picture, their annual compensation can jump into the range of tens of millions of dollars, like Pfizer’s Albert Bourla, Alex Gorsky from Johnson & Johnson, and AstraZeneca’s Pascal Soriot.
At the end of February, the U.S. was averaging 65,686 new COVID-19 cases per day. Fast-forward two months and that number is nearly identical at 64,814.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
It has been reported that Johnson & Johnson contacted Pfizer, Moderna, and AstraZeneca about investigating the clots and to “speak with one voice about safety.” However, both Pfizer and Modera declined, indicating that their vaccines were not associated with blood clots.
Although the data is not there, Pfizer’s chief executive officer, Albert Bourla, recently said he thought people will “likely” need a booster dose of a vaccine within 12 months of getting fully vaccinated. It’s possible, he also said, they will need to be vaccinated annually.
JOBS
IN THE PRESS